PinnyPeptide

FTPP-Adipotide vs Tirzepatide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

FTPP-Adipotide

Weight Management

Vasculature-targeting peptide that selectively destroys adipose blood vessels.

Peptide B

Tirzepatide

Weight Management

Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits.

Typical vial

5 mg

Typical dose

Per kg dosing (research-only) mcg

Half-life

~hours

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

2500-15000 mcg

Half-life

~5 days (120 hours)

FDA status

FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound …

FTPP-Adipotide effects

  • Selective destruction of white adipose tissue vasculature
  • Rapid weight and fat loss in primate models
  • Improved insulin sensitivity
  • Brown adipose tissue largely spared
  • Mechanism distinct from lipolytic / appetite-suppressing peptides

Tirzepatide effects

  • Industry-leading weight loss (up to 22.5% body weight in trials)
  • Superior glycemic control with high rates of HbA1c normalization
  • Dual incretin receptor activation for complementary metabolic benefits
  • Significant reduction in waist circumference and visceral fat
  • Improved cardiometabolic risk factors (lipids, blood pressure)
  • Treatment of moderate-to-severe obstructive sleep apnea in obesity

FTPP-Adipotide side effects

  • Renal toxicity (prohibitin expressed in kidney vasculature) — significant safety concern
  • Possible damage to other prohibitin-expressing vascular beds
  • Injection-site reactions
  • Limited human safety data
  • Acute inflammatory response from adipose vascular death

Tirzepatide side effects

  • Nausea (most common, particularly during dose escalation)
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Injection site reactions

FTPP-Adipotide dosing ranges

Animal research (rhesus monkey model)

0.43 mg/kg · Daily SubQ × 28 days · Per published protocol

Human self-experimentation

Not recommended · — · —

Tirzepatide dosing ranges

Type 2 diabetes (Mounjaro)

2500-15000 mcg · Once weekly (SubQ) · Ongoing as prescribed

Weight management (Zepbound)

2500-15000 mcg · Once weekly (SubQ, titrated over 20 weeks) · Ongoing as prescribed

FTPP-Adipotide vs Tirzepatide — common questions

What is the difference between FTPP-Adipotide and Tirzepatide?

FTPP-Adipotide: Vasculature-targeting peptide that selectively destroys adipose blood vessels. Typical dose Per kg dosing (research-only) mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.

Can you stack FTPP-Adipotide and Tirzepatide?

Stacking FTPP-Adipotide with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, FTPP-Adipotide or Tirzepatide?

FTPP-Adipotide is typically dosed: Daily SubQ × 28 days for Animal research (rhesus monkey model); — for Human self-experimentation. Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).

Are FTPP-Adipotide and Tirzepatide FDA approved?

FTPP-Adipotide: Not FDA approved. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free